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1. Introduction 
Cell function is dependent upon the co-ordinated and dynamic formation of complex 
interaction networks between molecules of diverse biochemical properties. These networks, 
or interactomes, are comprised of macromolecular biopolymers; proteins, DNA, RNA and 
polysaccharides, in addition to non-polymer compounds such as small molecular 
metabolites. This myriad of interactions is highly regulated and any perturbation or 
alteration has potential to result in disease. 
Profiling protein-protein interactions has been the major focus of interactomics in the past 
few years (Charbonnier et al. 2008) largely due to the advances in technological platforms 
that have the capacity to probe globally. Early efforts have included two-hybrid screens to 
identify binary binding interactions; more recent studies have used a range of mass 
spectrometry based methods to identify protein complexes that are a better reflection of 
multi-interactive nature of such complexes. Protein/small molecule interactions are equally 
important in modulating the function of their target proteins but few studies have analyzed 
these interactions on a large scale. The field is indeed still in its infancy due to difficulties in 
identifying metabolites but has recently benefitted from technological advances in mass 
spectrometry, data analysis software and metabolites database development for the 
measurement and identification of metabolites. The next step is to integrate metabolomic 
profiling to functional characterization of metabolic pathways by identifying systematically 
metabolite-protein interactions.  
Research efforts have in general been more focused on lipid-mediated interactions and this 
chapter reviews the global methods as well as their applications used to map lipid-protein 
interactomes based on mass spectrometry or arrays. The potential of these studies to deepen 
our understanding on the biological function of metabolites as protein effectors is also 
discussed. 
2. Metabolomics 
Metabolites are defined as small organic molecules produced and modified by a living 
organism as a result of cellular and physiological metabolism. These molecules constitute an 
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important fraction of the dry weight of a living cell ranging from 17 to 27 % in bacteria and 
mammalian cells respectively. They consist of a wide variety of small molecules with a vast 
chemical diversity, including amino acids, nucleotides, sugars and fatty acids that are 
central to all metabolic pathways existing in the cell. The precise number of metabolites 
produced in a cell at a certain time point is unknown but is estimated to range from a few 
hundreds in bacteria to a few thousands in plant and animal cells. Metabolic networks 
reconstructed from studies in yeast have indicated up to 1494 different metabolic 
compounds (Herrgard et al. 2008). The human metabolome database (version 2.5) embraces 
7982 compounds that have been experimentally confirmed (Wishart et al. 2009). These 
compounds have been further divided into 52 different classes. The number and diversity of 
possible metabolites is extensive and this entails that a significant proportion of proteins 
may form functional but also opportunistic interactions with metabolites. 
Overall metabolites constitute the metabolome of a cell, tissue or organism at a specific time 
and changes in metabolic profiles have enormous potential to understand cellular function 
and for clinical diagnostics (Vinayavekhin et al. 2010). To this effect, metabolomics has been 
applied to the general profiling of metabolites in biological samples, the discovery of 
biomarkers in diseases and the clinical screening of targeted compounds. Metabolomics 
gives an additional biologically relevant dimension to transcriptomics and proteomics and 
the integration of these data allows for a deeper understanding of physiological processes in 
normal and pathological states. While transcriptomics, proteomics and metabolomics allow 
the cellular inventory of biochemicals, an additional layer of data integration is still 
necessary to assess the mechanisms of regulation leading to a specific metabolic status. 
Computational-based metabolic flux analysis provides information on intracellular flux 
distributions of metabolic processes of a cell or an organism that can be integrated to data 
generated through transcriptomics, proteomics and metabolomics (Blank & Kuepfer 2010).  
The range and diversity of functional metabolites has been highlighted and it is beyond the 
scope of this review to critique the methods that are currently used for all metabolites. 
Rather we have chosen to focus on a subset of metabolites, lipids, and in particular inositol-
phospholipids, which are key regulators of numerous signalling pathways and which have 
been the most studied in recent years. 
3. Functional lipidomics: From lipidomics to lipid-protein interactomics 
The last 5 to 10 years have witnessed an incredible advancement in mass spectrometry and 
bioinformatics to analyse and identify systematically most lipids existing in biological 
samples at any one time and under different conditions in a specific entity (Wenk 2010; van 
Meer & de Kroon 2011). Cells contain thousands of lipids with a large chemical diversity 
and in light of recent advancement in lipid research, their classification has recently been 
updated by the LIPID MAPS initiative (Fahy et al. 2009). Lipidomics provide snapshots of 
the biochemical status of a cell and have the potential to complement transcriptomic and 
proteomic profiles. Integration of metabolomics, including lipidomics, to transcriptomics 
and proteomics analyses is expected to improve our understanding of metabolic pathways 
in health and diseases.  
Although metabolite profiling provides important information on the status of a cell or 
organism, there is still a lack of functional data. Recently a shift has occurred from profiling 
all existing metabolites in a cell, tissue or an organism (metabolomics) to understanding 
how they may affect cellular functions (functional metabolomics) by the identification of 
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metabolites-protein interaction networks. In this chapter, we have highlighted the methods 
as well as their applications used to map lipid-protein interactions in biological systems. 
3.1 Methods to identify lipid-protein interactions 
Small scale and large scale mapping of lipid-protein interactions methods have been 
developed using either targeted strategies studying a specific lipid or protein of interest 
(Figure 1) or large-scale strategies using lipid arrays or protein arrays (Figure 2). 
Protein capture using affinity-based pull down has been widely used in combination with 
mass spectrometry to identify lipid interactomes in particular (Figure 1). In these cases cell 
extracts are incubated with lipid conjugated to affinity matrices and bound proteins are 
identified by mass spectrometry (Krugmann et al. 2002; Scholten et al. 2006; Osborne et al. 
2007; Pasquali et al. 2007; Catimel et al. 2008; Catimel et al. 2009; Lewis et al. 2011).  
Opposite strategies to identify lipids bound to a selection of proteins or a particular protein 
of interest have also been developed (Tagore et al. 2008; Kim et al. 2011; Li & Snyder 2011) 
(Figure 1). Recombinant proteins can be purified and immobilised onto a solid support and 
exposed to a metabolite mixture obtained from cells or tissues where the protein is  
known to be expressed. Additionally, endogenous proteins or tagged proteins can be 
immunoprecipitated from a cell or tissue extract (Li et al. 2007; Urs et al. 2007). Metabolites 
that are bound to the isolated protein are eluted and identified by mass spectrometry. 
High-throughput screening strategies of these interactions have also been established using 
protein and small molecules microarrays (Lueking et al. 2005; Chen & Snyder 2010; Wu et al.  
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Fig. 1. Methods to identify lipid-protein interactions using targeted methods 
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Fig. 2. Methods to identify lipid-protein interactions using large-scale methods 
2011) (Figure 2). Microarrays are collections of hundreds to thousands of molecules 
immobilised on planar surfaces such as glass slides or nitrocellulose coated slides. Protein 
microarrays consist of individually expressed and purified proteins representing the 
complete or partial proteome known for a particular organism. Small molecules arrays 
consist of synthetic or naturally occurring molecules printed or spotted onto solid surfaces. 
To assess metabolites-protein interactions, protein arrays are exposed to fluorescently 
labelled metabolites (Zhu et al. 2001). Small molecules arrays are exposed to individual 
proteins (Rogers et al. 2011) or cellular lysates containing tagged proteins and interactions 
are detected using antibody recognising the specific  tag (Gallego et al. 2010). 
3.2 Lipid-protein interactomes 
Lipids represent the largest class of metabolites in cells and are involved in a wide variety of 
cellular functions (van Meer & de Kroon 2011). They are essential structural components of 
cellular membranes and function as energy stores, cellular signalling molecules and 
regulators of transcription factor. Recent lipidomics analyses in mammalian cells have 
highlighted the dynamic remodelling of different lipid molecules (Dennis et al. 2010). These 
molecules have therefore been the focus of un-biased and systematic interactome studies in 
an effort to further clarify the functions of these molecules.  
3.2.1 Phosphoinositide-protein interactomes mapping using lipid affinity matrices 
capture combined with MS of proteins 
Many studies have focused on the identification of phosphoinositides (PIs)-protein 
interactomes. Inositol phospholipids, a small subset of the total lipid pool function as key 
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regulators of numerous regulatory pathways (Toker 2002; Janmey & Lindberg 2004; Di 
Paolo & De Camilli 2006; Poccia & Larijani 2009). They function predominantly but not 
exclusively as sensors that recruit proteins and protein complexes to sites of synthesis in 
response to external cues (Lindmo & Stenmark 2006; Lemmon 2008). Target proteins possess 
well characterised domains within their structure that bind with varying affinity and 
specificity to the phosphorylated inositol head group. In addition, the hydrolysis of these 
lipids by phospholipase activities generate further second messengers such as 
diacylglycerols and polyphosphorylated inositols extending the influence of these lipids on 
cellular function and highlighting the need for further efforts to understand molecular 
mechanisms. A first step toward this would be to identify specific effector protein 
complexes that are regulated directly via binding and from this point of view proteomic 
methods and their applications are well placed to characterise globally the macromolecular 
complexes.  
A number of studies have focused on the identification of PI-binding proteins using affinity 
matrices to pull down potential PI interacting proteins from cellular lysates and subsequent 
mass spectrometry analyses. These studies are summarized in Table 1. In a study using a 
combination of PI affinity matrices, competitive lipid pull down and protein fractionation  
 
PI interactome 
analysed 
Method Cell type/subcellular compartment Reference 
PtdIns(3,4,5)P3 
PI conjugated beads and 
MS 
Pig leukocyte cytosolic extract 
(Krugmann 
et al. 2002) 
Mostly 
PtdIns(3,4)P2 
PI conjugated to 
cleavable S-S bond biotin 
+ streptavidin beads and 
MS 
Primary macrophage cytosolic 
extract 
(Pasquali et 
al. 2007) 
PtdIns(4,5)P2 
Biotinylated PI, 
streptavidine conjugated 
beads and MS 
Secretory granules from bovine 
adrenal chromaffin cells 
(Osborne et 
al. 2007) 
PtdIns(3,5)P2  
&  
PtdIns(4,5)P2 
PI conjugated beads or 
liposomes and MS 
LIM1215 colon cancer cell cytosolic 
extract 
(Catimel et 
al. 2008) 
PtdIns(3,4,5)P3 
PI conjugated beads or 
liposomes and MS 
LIM1215 colon cancer cell cytosolic 
extract 
(Catimel et 
al. 2009) 
PtdIns(4,5)P2 
PI conjugated beads and 
quantitative MS 
Neomycin extracted nuclear 
proteins isolated from murine 
erythroleukemia (MEL) cells 
(Lewis et al. 
2011) 
PtdIns(3,4)P2 
Stimulation of class I 
PI3K +/- wortmannin, 
biotinylated PI coupled to 
streptavidin beads and 
SILAC-based quantitative 
MS 
1321N1 astrocytoma membrane 
fractions 
(Dixon et al. 
2011) 
Table 1. Large-scale proteomics studies for the identification of PI binding proteins by MS 
www.intechopen.com
 
Integrative Proteomics 
 
368 
from pig leukocyte cytosol, 16 proteins were identified as PtdIns(3,4,5)P3 and 5 as 
PtdIns(3,4)P2 binding proteins by mass spectrometry (Krugmann et al. 2002). One of these 
proteins, ARAP3, a GTPase-activating protein, was further characterized as a functional 
PtdIns(3,4,5)P3 effector protein (Krugmann et al. 2002). Another study identified 10 known 
and 11 potentially novel PtdIns(3,4)P2 interacting proteins using cleavable biotinylated PI 
baits (Pasquali et al. 2007). None of these proteins overlapped with the ones identified in the 
previous study. 
In a more comprehensive study, Holmes and colleagues have characterized and compared 
the interactomes of PtdIns(3,5)P2 and PtdIns(4,5)P2 (Catimel et al. 2008) as well as 
PtdIns(3,4,5)P3 (Catimel et al. 2008; Catimel et al. 2009) determined from the cytosolic 
extracts of colon cancer cells expressing WT PI3 kinase. PIs immobilized either onto beads or 
incorporated into liposomes were used for protein capture from the cytosolic extracts. This 
led to the identification of 388 proteins in complex with PtdIns(3,5)P2 and/or PtdIns(4,5)P2 
(Catimel et al. 2008) and 282 proteins in complex with PtdIns(3,4,5)P3 (Catimel et al. 2009). A 
fraction of these were found to form complexes only with PtdIns(3,5)P2 (69), PtdIns(4,5)P2 
(146) or PtdIns(3,4,5)P3 (141). In addition significant overlaps were observed for these 
interactions, consistent with the promiscuous properties of some of these interactions. These 
studies represent the first comprehensive datasets of potential cytosolic PI-interacting 
proteins. In addition, the computational analyses of the molecular functions of proteins 
found in complex with cytosolic PI interactomes have highlighted roles in the regulation of 
GTPases, in transport/trafficking, cytoskeletal remodelling, phosphorylation-mediated 
post-translational modifications. 
The first organellar PI interactome was deciphered from secretary granules. Secretary 
granules were isolated from PC12 cells and 5 PtdIns(4,5)P2 binding proteins were identified 
by affinity lipid pull down and mass spectrometry. These interactions were all validated by 
lipid pull down and Western immunoblotting.  
PIs are also found in the nucleus (Irvine 2003; Hammond et al. 2004; Ye & Ahn 2008; Keune 
et al. 2011) and we have established a quantitative and proteomic method to identify 
PtdIns(4,5)P2 interacting proteins to gain insight into the PI-mediated nuclear functions 
(Lewis et al. 2011). The workflow of the method is schematised in Figure 3. The nuclear 
PtdIns(4,5)P2 interactome was characterized using PI-conjugated beads incubated in 
neomycin-extracted nuclear proteins mixtures and quantitative mass spectrometry using 
isotopic labeling of cells. Neomycin is known to bind to PIs with high affinity (Schacht 1978; 
Gabev et al. 1989) and we predicted that neomycin would compete for PIs in complex with 
proteins. Incubation of intact nuclei with neomycin resulted in the specific displacement of 
168 nuclear proteins harbouring a PI binding domain. Using neomycin extracts, 34 proteins 
were shown to interact with PtdIns(4,5)P2 in quantitative affinity purification using specific 
lipid conjugated matrices. Neomycin extraction of proteins represented an ideal preparation 
from which to affinity-purify PI-effector proteins using specific lipid conjugated matrices, 
avoiding the issues of sample complexity and dynamic range. Functional classification and 
enrichment analyses of the identified PtdIns(4,5)P2-interacting proteins pointed to roles in 
mRNA transcriptional regulation, mRNA splicing and protein folding. 
Dixon and colleagues have recently developed a three phase affinity enrichment method to 
quantitatively identify PtdIns(3,4)P2 effector proteins targeted to membranes (Dixon et al. 
2011). 1321N1 astrocytoma cells labelled with either light or heavy isotope were stimulated 
with bpV, a vanadate analogue, which induces high levels of PtdIns(3,4)P2, and in the 
presence or absence of wortmannin, an inhibitor of the PI3K pathway. After the isolation of  
www.intechopen.com
 
Functional Proteomics: Mapping Lipid-Protein Interactomes 
 
369 
K/R 
C12
K/R 
C13
N
uc
le
ar
 is
ol
at
io
n
N
eo
m
yc
in
ex
tr
ac
tio
n
of
n
uc
le
ar
pr
ot
ei
ns
Is
ot
op
ic
la
be
lli
ng
A
ff
in
it
y
ca
pt
ur
e
fr
om
 
ne
om
yc
in
ex
tr
ac
ts
+ control 
beads
+ PIP2 
beads
Eluate
Eluate
Mixed eluates
ran on 1D-
PAGE
m/z
LC-MS/MS of 
trypsinised gel slices
&
Quantification of 
ratios
Sample preparation
Lipid pull 
down
MS & Bioinformatics
Protein 
identification 
&
Functional 
analyses
 
Fig. 3. Quantitative characterisation of nuclear PI interactome by combining isotopic 
labelling of cells, affinity capture of proteins using PI matrices and mass spectrometry 
(Lewis et al. 2011): C13 K/R-labelled and C12 K/R-labelled nuclei were incubated with 5 mM 
neomycin. Displaced proteins were pulled down at equal concentration with control beads 
or PtdIns(4,5)P2 (PIP2)-conjugated beads. Proteins in mixed eluates were resolved by SDS-
PAGE, Coomassie stained and trypsin digested. Peptides were analysed by LC-MS/MS and 
13C/12C ratios were quantified using MSQuant (http://msquant.alwaysdata.net/msq/) 
and statistics were determined with StatQuant (van Breukelen et al. 2009). 
membranes, proteins specifically recruited to membrane fractions following bpV 
stimulation, were eluted with Ins(1,3,4)P3. Eluted proteins were subjected to ion-exchange 
chromatography, affinity capture with streptavidin beads pre-coupled to PtdIns(3,4)P2, 
followed by SDS-PAGE, LC-MS/MS and quantitative assessment of PtdIns(3,4)P2 effector 
proteins. Previously established PtdIns(3,4)P2–binding proteins, such as TAPP1 and Akt1-3, 
were identified, providing a strong proof of principle of the method. Overall 80-85 potential 
proteins were identified and this study provided the first quantitative MS-based 
identification of PtdIns(3,4)P2 effector proteins. Many but not all proteins harboured lipid 
binding domains. The binding characteristics of a novel binding protein, IQGAP1, to 
PtdIns(3,4)P2 were determined, demonstrating the existence of an atypical PI binding 
domain. 
Overall, studies based on affinity capture combined with mass spectrometry serve as useful 
resources and have the advantage to give a global view of the biological functions of 
proteins regulated by PIs in different cellular compartments. However a main drawback 
remains in the inability to discriminate between direct and indirect interactions through 
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associated proteins. Such analyses should be complemented by biochemical approaches 
analysing direct interactions for individual proteins. In addition, the potential existence of 
indirect protein complex networks can be assessed using known data for protein-protein 
interaction networks for the corresponding cell line or tissue explored. 
3.2.2 Lipid-protein interactomes mapping by protein immobilization or affinity 
purification and identification of lipids by MS 
Mass spectrometry has allowed the identification of lipids interacting with proteins both in 
targeted and large-scale systematic analyses. Different methods have been developed to 
affinity capture proteins followed by the extraction of bound lipids and their identification 
by tandem mass spectrometry. 
3.2.2.1 Targeted identification of ligands for nuclear receptors 
Several studies have focused on developing methods to identify physiological ligands for 
orphan nuclear receptors. Nuclear receptors represent a family of transcription factors that 
are activated by binding to specific small molecules to regulate the expression of specific 
genes.  
Saghatelian and colleagues have developed methods to identify indiscriminately the 
metabolites bound to recombinant proteins (Tagore et al. 2008). A protein of interest is 
purified from bacteria, immobilized on a solid support via a 6xHis or GST tag and incubated 
with a lipid extract obtained from cells known to express the corresponding protein. Eluted 
metabolites are analysed by LC-MS and the metabolite chromatogram profiles are compared 
computationally to control samples obtained from solid support alone. This strategy was 
applied for the nuclear receptors, peroxisome proliferator-activated receptors (PPAR) and  
(Kim et al. 2011) involved in lipid metabolism. Free fatty acids (FFA) such as arachidonic 
(C20:4), linoleic (C18:2) and oleic (C18:1) acids were identified as endogenous ligands for 
both nuclear receptors. Palmitoleic acid (C16:1) was also identified as a ligand for PPAR.  
In an alternative method, a physiological ligand was discovered for PPPAR by isolating 
the receptor from liver nuclear extracts obtained from mice either WT or lacking fatty acid 
synthase (FAS) (Chakravarthy et al. 2009). FAS is an enzyme that synthesize saturated FA 
which was previously shown to synthesize de novo a potential ligand for PPAR in liver 
cells (Chakravarthy et al. 2005). After elution of the receptor, lipids were extracted and 
subjected to tandem MS, which identified the phospholipid, 1-palmitoyl-2-oleyl-sn-glycerol-
3-phosphocholine as a FAS-dependent ligand of PPAR (Chakravarthy et al. 2009). This is a 
compelling approach to decipher endogenous ligand occupancy of orphan nuclear receptor 
in an in vivo setting. 
Sewer and colleagues were able to identify several phospholipids bound to another orphan 
nuclear receptor, steroidogenic factor 1 (SF-1) (Li et al. 2007) with roles in the regulation of 
steroidogenic hormones expression. SF-1 was immunoprecipitated from adrenocortical cells 
which express the receptor endogenously and phospholipids were analysed by LC-MS. 
Phosphatidic acid was found to be a major lipid bound to SF-1 and to activate the 
transcriptional activity of the receptor. A similar approach allowed the identification of linoleic 
acid (C18:2) as a ligand for another orphan nuclear receptor hepatocyte nuclear factor 4 
(HNF4) , affinity purified from mammalian cells (Yuan et al. 2009). Importantly the 
occupancy of the ligand was dependent upon the physiological condition studied: HNF4 was 
bound to linoleic acid when the receptor was isolated from livers of fed mice but not of fasted 
mice. Additionally the ligand did not have any effect on the transcriptional activity of HNF4.  
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3.2.2.2 Large scale identification of metabolite-protein interactions 
An affinity purification protocol in yeast was recently established by Snyder and colleagues 
to identify hydrophobic metabolites bound to 103 protein kinases as well as to a selection of 
proteins including 21 enzymes involved in the ergosterol biosynthetic pathways (yeast 
molecular analogue of cholesterol) (Li et al. 2010). In this case proteins were fused to an 
immunoglobulin binding domain and isolated from yeast extracts by affinity pull down. 
Metabolites interacting with the affinity purified proteins were extracted and identified by 
LC-MS. Control samples consisted of a yeast strain extract devoid of the corresponding 
fused protein. Such systematic analysis revealed that about 70% of the ergosterol 
biosynthetic enzymes and 20% of all protein kinases analyzed were bound to hydrophobic 
molecules. Known protein-metabolites interactions were observed but a majority of new 
interactions were also uncovered. Some interactions were unexpected and suggested 
important roles for ergosterol in the regulation of not only lipid biosynthetic pathways but 
also of many kinases, amongst which Ypk1 yeast kinase homologue to the mammalian 
kinase Akt.  
3.2.3 Large scale interactomics to identify lipid-protein interactions 
The magnitude of metabolites-protein interactions has been highlighted in large-scale 
screens in budding yeasts using different approaches using protein or lipid arrays (Zhu et 
al. 2001; Gallego et al. 2010). Using systematic approaches such as these, a comprehensive 
set of proteins can be simultaneously assessed for their potential interactions with lipids but 
also with other small molecules. 
Firstly, Snyder and colleagues developed protein chips for the yeast proteome of 
Saccharomyces cerevisiae. These were the first protein arrays for any organism to be engineered 
(Zhu et al. 2001). The yeast proteome array contained 5800 proteins fused to GST-6xHis and 
was screened for PI interactions using PIs assembled in liposomes containing 
phosphatidylcholine (PC) and an additional biotinylated lipid. PtdIns(3)P, PtdIns(4)P, 
PtdIns(3,4)P2, PtdIns(4,5)P2 or PtdIns(3,4,5)P3, containing liposomes were applied to the 
arrays, followed by an incubation with fluorescently-labeled streptavidin. Following the 
fluorescence detection of the arrays, 49 proteins were found to interact significantly with PIs 
compared to PC liposomes, with different affinities and specificities for the different PI 
molecules. Conventional methods were applied to confirm protein-PI interactions for 3 
proteins involved in glucose metabolism that were not previously expected to bind to PIs. 
The second screen reported is a large-scale analysis of yeast lipid-proteins interactions that 
was recently performed by Gavin and colleagues (Gallego et al. 2010). An opposite approach 
was used and lipid arrays were generated using 56 different lipids spanning the main 
classes of lipids found in yeast applied on nitrocellulose membranes. These arrays were 
incubated with cell extracts expressing single tandem affinity purification (TAP)-tagged 
proteins in S. cerevisiae. Interactions with 172 single TAP-tagged protein containing extracts 
were assessed for their potential interaction with the lipid array and gave rise to 530 
interactions involving 124 proteins and 30 lipids. Amongst the 56 lipids studied, PIs were 
represented by PtdIns(3)P, PtdIns(4)P, PtdIns(4,5)P2 and PtdIns(3,4,5)P3, and 86 proteins 
were found to bind PIs of which 77% harboured a lipid binding domain. PIs represented 
indeed the lipid category that interacted with most proteins, which is consistent with the 
wide range of cellular functions they are reported to take part into. Importantly, this study 
also assessed the quality of the data generated by the lipid array by comparing data 
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retrieved from the literature and from genetic interactions. In addition the identified 
interactions by lipid overlay were validated for 8 proteins chosen amongst the obtained 
dataset. Overall, Gavin and colleagues reported that 54% of the identified interactions were 
validated by additional genetic evidence, making this interactome dataset the most 
comprehensive resource for lipid biology. 
Unfortunately, very little overlap, accounting for about 5%, could be observed for PI-protein 
interactions between the 2 previously described studies despite an overlap of 88% of the 
proteins analysed (Zhu et al. 2001; Gallego et al. 2010). These contrasting datasets may be 
explained by different interaction properties being measured. For example, the protein chips 
may not allow the access of potential binding domain of all proteins to the phospholipids 
and therefore prevent potential interactions. In addition not all the proteins are 
overexpressed and purified as full length proteins or at sufficiently high level for the assay. 
As for the lipid array experiments, indirect interactions are also possible. 
Although extensive datasets are now available from PI interactomes in yeast and 
mammalian cell lines, the overlap between the PI interactomes determined in these different 
species is unknown. We have therefore attempted to compare the dataset obtained from 
PtdIns(4,5)P2 nuclear interactome studies (Lewis et al. 2011) to the datasets obtained in S. 
cerevisiae. Using InParanoid 7 (Ostlund et al. 2010), 18 yeast orthologues were recovered 
from the 34 murine proteins reported in the PtdIns(4,5)P2 nuclear interactome dataset. Out 
of the 18 yeast orthologues, 3 proteins were in common with PI binding proteins identified 
by protein chip lipid overlay by Snyder and colleagues (Zhu et al. 2001). These proteins are 
listed in Table 2. Cdc19 and Cct8, were found to interact with PtdIns(4)P in the yeast PI 
interactomics study. Cam1 was identified as a PtdIns(4,5)P2-interacting protein in the same 
study, which was consistent with our study. These findings certainly warrant further 
characterization of these proteins. In contrast, none of the 18 orthologues were found to be 
common to the dataset obtained from the lipid array screen by Gavin and colleagues 
(Gallego et al. 2010) and this may be explained by the following points. Firstly, the majority 
of proteins chosen in the lipid array screen were known to harbour at least one lipid binding 
domain (LBD) as defined by the online tools for protein domain assignment SMART, Pfam 
or SuperFamily, whereas none of the identified nuclear proteins harboured such domains 
but rather simple basic amino acid rich patches (Lewis et al. 2011). Secondly, the proportion 
of proteins annotated to the nucleus compartment analysed in the lipid array screen is not 
known. 
 
ORF (yeast) 
Gene name
(yeast) 
Uniprot ID 
(mouse) 
Gene name
(mouse) 
Protein description (mammalian) 
YAL038W Cdc19 P52480 Pkm2 
Isoform M2 of Pyruvate kinase 
isozymes M1/M2 
YJL008C Cct8 P42932 Cct8 T-complex protein 1 subunit theta 
YPL048W Cam1 Q9D8N0 Eef1g Elongation factor 1-gamma 
Table 2. List of genes found in common between the datasets obtained from the mammalian 
PtdIns(4,5)P2 nuclear interactome (Lewis et al. 2011) and the yeast PI interactome (Zhu et al. 
2001). Datasets that were compared include all yeast proteins found to bind PIs in the study 
by Zhu et al and 18 yeast orthologues retrieved from the 34 murine proteins identified in the 
PtdIns(4,5)P2 nuclear interactome. 
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4. Chemical proteomics for lipid pathway drug specificity validation 
Chemical proteomics has recently been used to explore the specificity of known drugs. In 
the case of drugs targeting lipid pathways, this method was used to identify all possible 
protein targets of a class I PI3K inhibitor, LY294002  (Gharbi et al. 2007). An analogue of 
the PI3K class I inhibitor LY294002, PI828, was immobilized onto epoxy-activated 
sepharose beads and used to pull out protein targets from whole cell extracts obtained 
from a human epithelial cell line (HeLa) and a mouse lymphoma B-cell line (WEHI231). 
Protein targets were eluted and identified by LC-MS/MS. This study demonstrated that 
this compound, bound not only to class I PI3Ks and other PI3K-related kinases, but also 
non-lipid kinases which was consistent with the inhibitory profile previously known for 
this compound. However novel targets were also identified which were reported to 
possibly explain some of the off-target cellular effects of this compound. The use of such 
proteomic approach has the potential to determine the specificity of known or new drugs 
at the cellular level as well as the potential cellular functions altered by the compound 
studied.  
5. Comparison of PI interactomics data to whole genome genetic screens 
Chemical genomics preceded the advent of chemical proteomics due to the completion of 
the S. cerevisiae Deletion Project which allowed whole genome genetic screens of different 
drugs. Such screen was performed to reveal new functions of PI metabolism by using 
wortmannin to identify genes which could confer altered sensitivity to the drug (Zewail et 
al. 2003). In yeast, wortmannin inhibits PtdIns(4)P kinase, Stt4p, and its inhibitory effects 
have been reported to be due to the depletion of PtdIns(4,5)P2 (Cutler et al. 1997). This 
screen allowed the identification of 591 genetic interactions due to wortmannin resistance 
and provided an overview of the actions of the PI pathway. New functions that were not 
previously attributed to the PI metabolic pathway were uncovered, namely DNA replication 
and DNA damage checkpoint, chromatin remodelling and proteasome-mediated protein 
degradation. 
A fraction of protein-protein interaction networks can be correlated to genetic interaction 
networks in yeast. Since wortmannin has been reported to affect the pool of PtdIns(4,5)P2, 
we assumed that a fraction of PtdIns(4,5)P2 effector proteins identified in physical screens 
would coincide with a fraction of the wortmannin genetic interaction screen. We have 
therefore compared our PtdIns(4,5)P2 interaction networks obtained from mammalian 
nuclei to the wortmannin genetic screen performed in yeast. We were able to identify 4 
genes in common between the physical and the genetic interaction datasets and these are 
listed in Table 3 and shown in the Venn diagram in Figure 4. In addition, 1 of these genes, 
Cam1, corresponding to the mammalian orthologue Eef1g (Elongation factor-1 ), was also 
found to be common to the PI-protein interactomics study from Snyder and colleagues (Zhu 
et al. 2001). Interestingly, Cam1 was initially characterised as a possible phospholipid 
binding protein (Creutz et al. 1991; Kambouris et al. 1993), which would therefore be 
consistent with both physical and genetic studies.  
Moreover, comparing the datasets obtained from the PI interactome study from Zhu et al to 
the wortmannin genetic screen from Zewail et al identified 18 proteins in common (14%). 
The overlapping data is presented as a Venn diagram in Figure 4.  
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ORF (yeast) 
Gene name 
(yeast) 
Uniprot ID 
(mouse) 
Gene name 
(mouse) 
Protein description (mammalian) 
YER081W Cam1 Q9D8N0 Eef1g Elongation factor 1-gamma 
YDR518W Eug1 P27773 Pdia3 
Protein disulfide-isomerase A3 
precursor 
YMR072W Abf2 
P63158 
P30681 
Hmgb1 
Hmgb2 
High mobility group protein B1 
High mobility group protein B2 
Table 3. List of proteins found in common in the PtdIns(4,5)P2 nuclear interactome study 
(Lewis et al. 2011) and in the wortmannin genetic screen in S. cerevisiae (Zewail et al. 2003). 
Datasets included 18 yeast orthologues retrieved from the 34 murine proteins identified in 
the PtdIns(4,5)P2 nuclear interactome and all of the genes that conferred wortmannin 
resistance when deleted individually in yeast. 
 
128 13
567
Zhu et al (149) Lewis et al (18)
1
Zewail et al (588)
2
2
 
Fig. 4. Venn diagram representation of common proteins identified in PI interactome studies 
(Zhu et al. 2001; Lewis et al. 2011) and chemical genomics screen using wortmannin (Zewail 
et al. 2003). Datasets that were compared included all yeast proteins found to bind PIs in the 
study by Zhu et al, the 18 yeast orthologues retrieved from the 34 murine proteins identified 
in the PtdIns(4,5)P2 nuclear interactome (Lewis et al) and all of the genes that conferred 
wortmannin resistance when deleted individually in yeast (Zewail et al). 
6. Conclusion: Challenges and future direction in lipid-protein interactomics 
Systematic and unbiased proteomics studies have answered some of the questions 
regarding lipid-mediated pathway functions. Most studies have focused on mapping PI 
interactomes from separate cellular compartments while more recent studies have expanded 
our knowledge to other lipid subclass interaction networks. In addition, the availability of 
genome wide genetic screen in yeast allows the potential discovery of overlaps with 
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physical interactions datasets, thereby strengthening interaction data. Identifying lipid 
binding proteins has indeed provided some insights into the possible biological functions of 
the corresponding lipids mainly by inference of protein function. The next challenge is to 
assign biological functions to each of these interactions. 
Several large scale interactome studies have shown little overlap in findings and both false 
positive and false negative are likely to be generated by these types of methods. Overall a 
great body of data is now indeed available and studies will still be required to further 
validate these interactions at the biochemical and cellular level, in vitro and in vivo. 
The reported interactomes are at present synonymous with a static view of molecular 
complexes and this raises therefore a number of questions and challenges worthy of further 
scrutiny. What are the lipid-protein interactomes at the sub-cellular level? How are these 
interactions regulated in time and space? What are the mechanisms of regulation? What are 
the modes of interactions? Moreover do these interactions affect other types of interactions 
mediated by other macromolecules? This last question entails probably a new challenge in 
systems biology, i.e. the integration of data obtained from lipid-protein interactomes to 
those obtained from other protein-macromolecule interactomes.  
Finally, lipids, in particular signalling lipids such as PIs, but also eicosanoids, sphingolipids 
and fatty acids are known to control critical cellular functions and the alteration of lipid-
mediated pathways is known to contribute to the development of pathologies, such as 
chronic inflammation, cancer, neurodegenerative and metabolic diseases (Pendaries et al. 
2003; Wymann & Schneiter 2008; Skwarek & Boulianne 2009). Newly acquired knowledge 
on lipid-protein interactions may pinpoint potential lipid effectors that may become targets 
for drug therapies. This may become even more relevant if changes in lipid-protein 
networks are identified in pathological states. 
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